Resolute zotarolimus-eluting stents demonstrated similar 3-year rates of target vessel failure compared to XIENCE V everolimus-eluting stents (12.1% vs 13.4%, p=0.50).
RCT (n=1,391)
Randomized
Does the Resolute zotarolimus-eluting stent improve target vessel failure compared to the XIENCE V everolimus-eluting stent in patients with stable angina or non-ST-elevation acute coronary syndromes?
Three-year follow-up of the TWENTE trial demonstrates sustained and similar safety and efficacy between second-generation zotarolimus-eluting and everolimus-eluting stents.
Absolute Event Rate: 12.1% vs 13.4%
p-value: p=0.50
AIMS: To assess three-year clinical outcome following randomised use of the second-generation Resolute zotarolimus-eluting stent (ZES) and the XIENCE V everolimus-eluting stent (EES). For Resolute ZES and randomised use, outcome data ≥3 years are relatively scarce. METHODS AND RESULTS: The TWENTE trial examined 1,391 patients with stable angina or non-ST-elevation acute coronary syndromes, of whom 21.6% were diabetics, 70.1% had complex B2 or C lesions and 77.4% had "off-label" indications for DES use. Three-year follow-up data were obtained in 1,381 patients (99.3%; 10 withdrawals). Adverse clinical events were independently adjudicated. The primary endpoint target vessel failure (TVF), a composite of cardiac death, target vessel-related myocardial infarction and clinically indicated target vessel revascularisation, was 12.1% for Resolute ZES and 13.4% for XIENCE V EES (p=0.50). Cardiac death rates were 1.9% vs. 3.5% (p=0.06); the other individual components of TVF also showed no significant between-group differences. The rates of definite-or-probable stent thrombosis (1.4% vs. 1.6%, p=0.82) and very late stent thrombosis (0.6% vs. 0.4%, p=1.0) did not differ between the groups. CONCLUSIONS: Three-year follow-up data of patients included in the randomised TWENTE trial demonstrated similar and sustained safety and efficacy of Resolute ZES and XIENCE V EES.
Löwik et al. (Sun,) conducted a rct in Stable angina or non-ST-elevation acute coronary syndromes (n=1,391). Resolute zotarolimus-eluting stent (ZES) vs. XIENCE V everolimus-eluting stent (EES) was evaluated on Target vessel failure (TVF), a composite of cardiac death, target vessel-related myocardial infarction and clinically indicated target vessel revascularisation (p=0.50). Resolute zotarolimus-eluting stents demonstrated similar 3-year rates of target vessel failure compared to XIENCE V everolimus-eluting stents (12.1% vs 13.4%, p=0.50).